Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jun;19(6):313.
doi: 10.1038/s41574-023-00839-y.

GLP1 receptor agonists for Wolfram syndrome?

Shimona Starling  1
Affiliations
Comment

GLP1 receptor agonists for Wolfram syndrome?

Shimona Starling. Nat Rev Endocrinol. 2023 Jun.
No abstract available

PubMed Disclaimer

Comment on

  • GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.
    Gorgogietas V, Rajaei B, Heeyoung C, Santacreu BJ, Marín-Cañas S, Salpea P, Sawatani T, Musuaya A, Arroyo MN, Moreno-Castro C, Benabdallah K, Demarez C, Toivonen S, Cosentino C, Pachera N, Lytrivi M, Cai Y, Carnel L, Brown C, Urano F, Marchetti P, Gilon P, Eizirik DL, Cnop M, Igoillo-Esteve M. Gorgogietas V, et al. Diabetologia. 2023 Jul;66(7):1306-1321. doi: 10.1007/s00125-023-05905-8. Epub 2023 Mar 30. Diabetologia. 2023. PMID: 36995380 Free PMC article.

References

Original article
    1. Gorgogietas, V. et al. GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models. Diabetologia https://doi.org/10.1007/s00125-023-05905-8 (2023) - DOI - PubMed
Related article
    1. Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201–216 (2023) - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources